Thinking of joining a study?

Register your interest

Become a volunteer?

NCT07078604 | RECRUITING | Anatomic Stage IV Breast Cancer AJCC v8

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
Sponsor:

University of Washington

Brief Summary:

This phase II trial studies how well a cancer vaccine called STEMVAC works in combination with chemotherapy in treating patients with PD-L1 negative, triple-negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). STEMVAC is designed to target proteins that are expressed on breast cancer stem cells, and it is believed to work by boosting the immune system to recognize and destroy the invader tumor cells that are causing the disease. The allowable combination chemotherapy includes: (1) Paclitaxel is in a class of chemotherapy medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. (2) Docetaxel is in a class of chemotherapy medications called taxanes. It stops tumor cells from growing and dividing and may kill them. (3) Cisplatin is in a class of chemotherapy medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. (4) Carboplatin is in a class of chemotherapy medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. (5) Doxorubicin is in a class of chemotherapy medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. (6) Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. (7) Eribulin is in a class of chemotherapy medications called microtubule dynamics inhibitors. It works by stopping the growth and spread of tumor cells. Giving STEMVAC in combination with chemotherapy may be an effective treatment for PD-L1 negative metastatic triple-negative breast cancer.

Condition or disease

Anatomic Stage IV Breast Cancer AJCC v8

Metastatic Triple-Negative Breast Carcinoma

Intervention/treatment

CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine

Cisplatin

Computed Tomography

Computed Tomography Assisted Biopsy

Docetaxel

Doxorubicin

Eribulin

Paclitaxel

Pegylated Liposomal Doxorubicin Hydrochloride

Sargramostim

Ultrasound-Guided Biopsy

Biospecimen Collection

Carboplatin

Positron Emission Tomography (PET)

Phase

PHASE2

Detailed Description:

OUTLINE: Patients receive one of the following chemotherapy regimens, per the treating physician's discretion, in the absence of disease progression or unacceptable toxicity: 1) Paclitaxel every 21 days; paclitaxel on days 1, 8, and 15 every 28 days; paclitaxel on days 1 and 8 every 21 days; or docetaxel every 21 days; 2) Carboplatin every 21 days; carboplatin every 28 days; carboplatin on days 1 and 8 every 21 days; or cisplatin every 21 days; 3) Doxorubicin every 21 days; or liposomal doxorubicin every 28 days; OR 4) Eribulin on days 1 and 8 every 21 days. Patients receive 3 priming doses of STEMVAC with sargramostim intradermally (ID) every 21-28 days (7-10 days after each chemotherapy administration or during the off week of weekly chemotherapy), 2 booster STEMVAC/sargramostim doses at 4 and 7 months after 3rd priming dose, and then every 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) or ultrasound-guided biopsy, for research purposes, on study, as well as CT or positron emission tomography (PET) scans and blood sample collection throughout the study. In addition, patients may also undergo CT or ultrasound-guided biopsy, for research purposes, during screening. After completion of study treatment, patients are followed up at 21 or 28 days and then every 6 months for 3 years.

Study Type : INTERVENTIONAL
Estimated Enrollment : 20 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Phase II Trial of the Immunogenicity of a DNA Plasmid-Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes From Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDH3, CD105) in Patients With Metastatic Triple-Negative Breast Cancer
Actual Study Start Date : 2026-04-11
Estimated Primary Completion Date : 2027-04-30
Estimated Study Completion Date : 2028-06-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Patients must be at least ≥ 18 years of age
  • * Note: Because no dosing or adverse event (AE) data are currently available on the use of STEMVAC in patients \< 18 years of age, children and adolescents are excluded from this study, but will be eligible for future pediatric trials, if applicable
  • * Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status Score of ≤ 2
  • * Histologically confirmed triple-negative breast cancer
  • * Tumors with estrogen receptor (ER)-low (≤ 5%) or negative and progesterone receptor (PR)-low (≤ 5%) or negative will be included
  • * HER2-negative or HER2-low will be fined by the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2023 "Human Epidermal Growth Factor Receptor 2 (HER2) Breast Testing Guideline Update" which reaffirms the 2018 "HER2 Breast Testing Guideline Focused Update"
  • * Tumor is negative for PD-L1 marker testing per standard of care antibodies/clones in breast cancer at time of eligibility
  • * Metastatic disease that is measurable based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or PET Response Criteria in Solid Tumors (PERCIST). Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
  • * Have at least 1 site of disease confirmed by the treating oncologist that could be biopsied during treatment. This site should not be a site that is used to determine measurable disease for efficacy purposes. Lesions that will be biopsied should not be in a previously irradiated area unless progression has been demonstrated in such lesions
  • * Patients should not have received any prior cancer immunotherapy in the metastatic setting
  • * Prior Food and Drug Administration (FDA)-approved antibody drug conjugates are allowed
  • * Patients are appropriate candidates to receive standard of care chemotherapy as per treating oncologist's clinical judgement
  • * NOTE: Only chemotherapy partners listed in the protocol are allowed to be administered in metastatic setting concurrently with STEMVAC vaccine
  • * Patients who have received prior neoadjuvant or adjuvant chemotherapy are allowed
  • * A minimum of 14 days washout since last systemic therapy or any palliative radiotherapy is required
  • * Treatment with a bisphosphate or denosumab concurrently with protocol-specific therapy is allowed while on study (it is not exclusionary)
  • * Patients must be at least 28 days post systemic steroids prior to enrollment, unless this is a steroid administered concurrently with chemotherapy or used as part of prophylaxis to prevent intravenous (IV) contrast reactions
  • * Must have recovered from major infections and/or surgical procedures; and in the opinion of the investigator, not have any significant active concurrent medical illnesses or condition precluding protocol treatment
  • * Willing to undergo up to two serial biopsies while on study
  • * White blood cell (WBC) ≥ 2500/mm\^3 (Within 28 days of receiving first study vaccine)
  • * Lymphocyte count ≥ 500/mm\^3 (Within 28 days of receiving first study vaccine)
  • * Absolute neutrophil count (ANC) ≥ 1000/μL (Within 28 days of receiving first study vaccine)
  • * Hemoglobin (Hgb) ≥ 9 g/dl (Within 28 days of receiving first study vaccine)
  • * Platelets ≥ 75,000/μL (Within 28 days of receiving first study vaccine)
  • * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), except patients with Gilbert's syndrome in whom total bilirubin must be \< 3.0 mg/dL (Within 28 days of receiving first study vaccine)
  • * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 1.5 X institutional ULN (Within 28 days of receiving first study vaccine)
  • * Creatinine ≤ 1.5 X ULN mg/dL or creatinine clearance \> 60 ml/min (Within 28 days of receiving first study vaccine)
  • * Patients of child-bearing potential must agree to use dual methods of contraception and have a negative urine pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a person of child-bearing potential. Acceptable methods of contraception are abstinence, condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. Effective methods of contraception must be used throughout the study until the end of treatment on study
Exclusion Criteria
  • * Patient has received more than one line of prior therapy in metastatic setting
  • * Patients with tumors that are PD-L1-positive
  • * Enrollment in a concurrent interventional clinical trial. Biomarker or tissue collection or any other non-interventional clinical trial enrollment is allowed
  • * Patients with any of the following cardiac conditions
    • * Symptomatic restrictive cardiomyopathy
    • * Dilated cardiomyopathy
    • * Unstable angina within 4 months prior to enrollment
    • * New York Heart Association functional class III-IV heart failure on active treatment
    • * Symptomatic pericardial effusion
    • * Patients with any autoimmune disease or comorbidities requiring chronic steroids or immunosuppressants
    • * Known hypersensitivity reaction to the granulocyte-macrophage colony stimulating factor (GM-CSF) adjuvant; any known contra-indication to GM-CSF
    • * A non-breast malignancy requiring radiation or systemic therapy within last 5 years
    • * Pregnant and breastfeeding individuals
    • * Known history of human immunodeficiency virus (HIV) infection, hepatitis B (e.g., hepatitis B virus surface antigen \[HBsAg\] reactive), or hepatitis C (e.g., hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] \[qualitative\] is detected)
    • * Major surgery within the 4 weeks prior to initiation of study vaccine
    • * Must be 14 days between a non-study and non-live vaccine and any STEMVAC vaccination
    • * Note: The minimum of 14 days does not apply to the tetanus and diphtheria (Td) vaccine
    • * Any condition that may interfere with the patient's participation in the study per treating physician
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Location Details

NCT07078604

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Washington

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, United States, 98109